Upstream Bio
Upstream Bio Inc is an American clinical-stage biopharmaceutical enterprise focused on developing novel monoclonal antibody therapies for severe inflammatory and allergic diseases. The company advances verekitug (UPB-101), a recombinant monoclonal antibody targeting the TSLP receptor to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease (COPD). Principal revenue is currently driven through development capital raised, research milestones, and strategic licensing partnerships ahead of commercial market authorization. Core end markets encompass allergy and immunology clinics, pulmonology medical centers, and severe inflammatory disease prescription patients globally. Upstream Bio holds an innovative position in the biopharmaceutical sector as a specialized developer of TSLP receptor-targeted biologics for respiratory disorders. The company is headquartered in Waltham, Massachusetts, and its common stock trades on the Nasdaq Global Market.
2 of the funds FundTelligence covers report a position in Upstream Bio.
- Legal name
- Upstream Bio Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
Funds holding Upstream Bio
- SEB Läkemedelsfond — SEB · 0.34 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.01 % (full portfolio disclosed, October 2026)